Business Wire

TOSHIBA-MATERIALS

Share
Toshiba Materials in Major Investment to Increase Silicon Nitride Ball Production Capacity

Toshiba Materials Co., Ltd. (President: Katsuaki Aoki) today announced a major investment in a new manufacturing facility for silicon nitride balls on the same site as its headquarters in Yokohama, Japan. The project has a budget of over 5-billion yen (approx. US$38 million) and is expected to see production start in November 2023. It will increase capacity by 50% against fiscal year 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719006169/en/

Continued advances in automobile electrification requires solutions that go beyond higher voltage batteries and shorter charging times. One measure to reduce costs and improve performance is the integration of motors and inverters. Although this increases risk of electrolytic corrosion[1] in motor bearings[2] , the problem can be overcome with hybrid bearings, which replace standard steel balls with ceramic balls with steel inner and outer races. Advantages of high reliability, excellent strength and superior wear resistance are increasingly positioning ceramic balls as the solution of choice.

Toshiba Group has long recognized the potential of fine ceramic products, and won basic patents for silicon nitride compounds as early as 1974. Today, Toshiba Materials, spun off from Toshiba in October 2003, continues to advance R&D and manufacturing of silicon nitride balls, recognized for their reliability and for delivering the highest mechanical performance of any silicon balls. Its experience and record of success in bearing balls that meet demands for high speed rotation and anti-electrolytic corrosion, including machine tools, wind power generators and rolling stock, have won the company about 50% of the world market[3] . With significant increases in demand for bearings for electric vehicles on the horizon, Toshiba Materials has now decided to make this significant investment in increasing capacity.

The new production facility will be built on the company’s headquarters site, where an old building, no longer in use, will be demolished to make way for it. The new facility should be seen as the first phase of expansion, and Toshiba Materials is already considering further expansions to meet future demand growth.

Toshiba Materials will continue stable supply of high quality products, and will contribute to increased use of environmentally friendly electric vehicles.

Features of silicon nitride balls

  • Low density: less than half the weight of a steel ball of the same size
  • High heat resistance
  • Resistant to electrolytic corrosion, as it is an insulator
  • Resistant to corrosion and rust caused by acids and alkalis
  • A non-magnetic material, not easily affected by a strong magnetic field

1 Electrolytic corrosion: damage to a bearing caused by a current flowing through it.
2 Bearing: A part that allows a shaft to rotate smoothly in a machine. Formed with an inner race, balls, and outer race.
3 Toshiba Materials’ investigation, July 2022

About Toshiba Materials

Toshiba Materials Co., Ltd. (http://www.toshiba-tmat.co.jp/en/ ) was spun off from Toshiba Corporation in 2003. With material designing technology as its core capacity, Toshiba Materials supplies materials and components essential for society’s development. Main products include metallic materials, components, fine ceramics parts and chemical materials. In the year ended March 31, 2021, net sales totaled 24.3 billion yen (approx. USD 210 million).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly

Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release

Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit

Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release

New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc

LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release

Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital

Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release

This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye